Back to Search
DR. HANNAH M FINE DO
DO
Neuromusculoskeletal Medicine & OMM Physician
NPI: 1528231636Individual
Specialties, Licenses & Credentials
Neuromusculoskeletal Medicine & OMM PhysicianPrimary
Neuromusculoskeletal Medicine & OMM
Code: 204D00000X
DO164332(OR)
Research & Publications (20)
Acute posterior multifocal placoid pigment epitheliopathy following varicella vaccination.
PMID 18728052·Br J Ophthalmol·2010
5-case
Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
PMID 18784620·Retina·2009
5-case
Acute zonal occult outer retinopathy in patients with multiple evanescent white dot syndrome.
PMID 19139340·Arch Ophthalmol·2009
5-case
Outcomes of 77 consecutive cases of 23-gauge transconjunctival vitrectomy surgery for posterior segment disease.
PMID 17544779·Ophthalmology·2007
8-other
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
PMID 18056189·Clin Cancer Res·2007
3-trial
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
PMID 12805330·J Clin Oncol·2003
3-trial
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
PMID 10673511·J Clin Oncol·2000
3-trial
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
PMID 19562255·J Neurooncol·2010
3-trial
Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube.
PMID 19668550·Clin Ophthalmol·2009
5-case
Subfoveal pigment changes in patients with longstanding epiretinal membranes.
PMID 19232558·Am J Ophthalmol·2009
8-other
Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes.
PMID 19190341·Cancer Res·2009
8-other
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
PMID 19512898·Cornea·2009
5-case
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma.
PMID 19427293·Cell Stem Cell·2009
7-preclinical
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
PMID 19114704·J Clin Oncol·2009
3-trial
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes.
PMID 19244127·Cancer Res·2009
8-other
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
PMID 19636006·J Clin Oncol·2009
3-trial
Rembrandt: helping personalized medicine become a reality through integrative translational research.
PMID 19208739·Mol Cancer Res·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 534 PLEASANT VIEW WAY NW, SUITE 100
ALBANY, OR 97321 - Phone
- (541) 812-5656
Quick Facts
- NPI
- 1528231636
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile